What timeframe is specified for initiating systemic therapy for pathologically staged NSCLC patients?

The specified timeframe for initiating systemic therapy for pathologically staged non-small cell lung cancer (NSCLC) patients is crucial for optimizing treatment outcomes. Timely initiation of therapy is associated with improved survival rates and overall patient prognosis.

In clinical practice, starting systemic therapy within three months of surgical resection for pathologically staged NSCLC is generally recommended. This window allows for the treatment of any residual disease that may remain after surgery, which is vital for reducing the risk of recurrence. Delaying therapy beyond this timeframe has been linked to poorer outcomes, as cancer cells can proliferate and become more resistant to treatment.

This recommendation is informed by clinical guidelines and studies that demonstrate the benefits of early intervention in managing NSCLC. Following the three-month timeframe helps ensure that patients receive the necessary therapeutic support while their disease remains manageable.